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Introduction: Pancreatic cancer often recurs following surgery suggesting new operative approaches are required. 
Fluorescence-guided surgery aims to assist surgeons in identifying tumour intraoperatively to facilitate complete resection. 
However, the ideal contrast agent for this purpose is not yet determined. The Rose criterion states that accurate image-
guided surgery requires a Tumour-to-Background Ratio of contrast agent greater than 5. We investigated the potential of 
5-aminolevulinic acid (ALA) for this purpose. 
 
Methods: Pancreatic cancer cell lines CFPAC-1 and PANC-1 were compared with the control pancreatic ductal cell line 
H6c7. Cells were seeded on day 1 and fluorescence measured on day 4 following 4, 8, 24 or 48 hours incubation with 0.25, 
0.50, 0.75 or 1.00mM ALA. Fluorescence was measured using a plate reader and microscopy. 
 
Results: The maximum ALA-induced fluorescence for CFPAC-1 and PANC-1 was achieved after 48 hours incubation 
with 0.50mM ALA. Compared to cells incubated without ALA, a relative fluorescence increase of 39.4-fold in CFPAC-1 
and 2.7-fold in PANC-1 was seen. ALA concentrations above 0.50mM did not result in higher fluorescence. In contrast, 
the control cell line H6c7 showed progressively increasing fluorescence with increasing ALA concentrations. The highest 
cancer/control cell fluorescence ratios for ALA were after 48 hours incubation with 0.25mM ALA; 122.9 in CFPAC-1 and 
9.7 in PANC-1.  
 
Conclusion: ALA-induced fluorescence in CFPAC-1 is significantly higher than the control cell line H6c7. PANC-1 
achieved only mildly increased fluorescence compared to H6c7. ALA has the potential to provide an adequate level of 
fluorescence for image-guided pancreatic surgery in ALA-susceptible cancers. 
 






Despite advances in oncological treatments over the last few decades, five-year survival from pancreatic cancer remains 
extremely low (2.9% in 1980-1981 and 3.3% in 2010-2011, data for England and Wales)1. The majority of  patients (60%) 
are diagnosed with stage 3 or 4 disease due to aggressive tumor biology and the late onset of symptoms2. As a result, only 
10% of patients will undergo curative-intent surgery and only 28% will receive chemotherapy2,3. Even for those undergoing 
curative-intent resection, local disease recurrence is common (24%-40%)4–6. Reasons for this include anatomical 
restrictions to more radical surgery and early vascular and perineural invasion with micrometastases7. 
 
Fluorescence-guided surgery 
Fluorescence-guided surgery (FGS) aims to assist in the intraoperative identification of tumour to aid resection. At present,  
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surgeons rely on inspection and palpation of tissues to determine the location and extent of tumour, with preoperative 
information usually provided by non-invasive imaging such as Computerized Tomography (CT) and Magnetic Resonance 
Imaging (MRI). Intraoperative imaging techniques (such as ultrasound) are only helpful at the beginning of the procedure 
before the tissue planes become distorted once resection begins. In addition, laparoscopy has removed the tactile element 
of surgery, making the visual identification of residual tumour the most significant (and often only) intraoperative real time 
diagnostic tool. For oncological FGS, fluorescent contrast agents are needed that are taken up avidly by tumour cells but 
not by surrounding non-neoplastic tissue. The Rose criterion states that accurate image-guided surgery requires a signal-
to-noise ratio (i.e. tumour-to-background tissue ratio) of greater than 5.8 A suitable fluorescent contrast agent for pancreatic 
cancer resection has not yet been identified. 
 
5-aminolevulinic acid 
5-aminolevulinic acid (ALA) is a naturally occurring amino acid that forms an early substrate in the haem biosynthesis 
pathway. Protoporphyrin IX (PpIX), the penultimate molecule in the pathway, fluoresces red when excited with blue/violet 
light with a peak emission at 635 nm9. The addition of exogenous ALA leads to an accumulation of PpIX that can be 
exploited for the purpose of FGS. Although not specifically targeted to pancreatic cancer, there is preferential accumulation 
of ALA-induced PpIX fluorescence in many neoplastic tissues when compared to surrounding non-neoplastic tissues 10,11.  
 
ALA has clinical approval for use in FGS in grade III and IV malignant gliomas12. There is also evidence that ALA FGS 
could be used in a number of other malignancies, such as ovarian and renal cell cancers13,14. However, research on the use 
of ALA in pancreatic cancer is limited. A recent prospective study investigated the use of ALA in the detection of peritoneal 
metastases compared to standard surgery from 138 patients with known peritoneal disease from a variety of cancers 
(appendiceal, ovarian, mesothelial, colorectal, gastric and pancreatic)15. Although only 44.2% of the cohort had their 
peritoneal metastases identified using ALA, three out of the four patients with metastatic pancreatic cancer had their 
metastases identified.  
 
Aim 
Our aim was to investigate the degree of ALA-induced PpIX fluorescence in the two pancreatic cancer cell lines CFPAC-
1 and PANC-1 compared to the control cell line H6c7 (an immortalized non-tumorigenic pancreatic ductal cell line with 






CFPAC-1 was purchased from ECACC (European Collection of Authenticated Cell Cultures, Salisbury, United Kingdom), 
PANC-1 was purchased from RIKEN BioResource Centre (RIKEN BRC, Tsukuba, Japan), and H6c7 from Kerafast 
(Kerafast, Inc., Boston, USA). PANC-1 was cultured in Dulbecco’s modified Eagle’s medium containing 4.5g L-1 glucose 
and 0.58 g L-1 L-glutamine (Lonza®) supplemented with 10% Fetal Bovine Serum (FBS) (Gibco™). CFPAC-1 was 
cultured in Iscove’s modified Dulbecco’s medium containing 4.5g L-1 glucose, 4.0mM L-glutamine and HEPES buffer 
(Gibco™) supplemented with 10% FBS. H6c7 was cultured in Keratinocyte serum free media with L-glutamine, epidermal 
growth factor, bovine pituitary extract (Gibco™) and 1% antibiotic/antimycotic. Cells were cultured in 75cm2 tissue culture 
flasks (Techno Plastic Products®) in a humidified incubator at 37.0ºC with 5% CO2. Cells were trypsinized when ~80% 
confluent with 0.5% trypsin-EDTA (Gibco™) and passaged at a split ratio of 1:4. 
 
Fluorescence microscopy 
Cells were seeded on Fluorodishes on day 1 and had fluorescence microscopy performed on day 3. Prior to imaging, cells 
were incubated for either 4 or 24 hours with 0.0, 0.25, 0.5, 0.75 or 1.0mM ALA (Sigma-Aldrich®) in serum-free culture 
media. After the appropriate exposure time, cells were washed three times in Phosphate Buffered Saline (PBS), fixed in 
4% formaldehyde for 20 minutes, and washed again three times in PBS before having images taken on an Olympus® 
BX63 fluorescence microscope. 
 
Quantitative fluorescence 
Cells were seeded onto 96 well plates (Techno Plastic Products®) on day 1 and had fluorescence measured on day 4 using 
an Infinite® 200 PRO plate reader (excitation wavelength 420nm, emission wavelength 635nm). Prior to fluorescence 
measurement, cells were incubated with the aforementioned ALA hydrochloride concentrations in serum-free media for 4, 
8, 24 or 48 hours and washed twice in PBS immediately prior to reading.  
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CFPAC-1 readily converted ALA into PpIX resulting in strong red fluorescence at both 4 and 24 hours (Figure 1). In 
contrast, PANC-1 showed almost no red fluorescence at any ALA concentration at either time point. H6c7 showed minimal 
PpIX fluorescence at lower concentrations and time points but started to show some fluorescence at 1.0mM ALA at both 
4 and 24 hours. 
 
Figure 1 Fluorescence of pancreatic cell lines CFPAC-1, PANC-1 and H6c7 following 4 and 24 hours incubation with ALA* 
 
 
*Excitation 545nm, emission 620nm, exposure time 10 seconds 
 
Quantitative fluorescence 
The maximum ALA-induced fluorescence for CFPAC-1 and PANC-1 was achieved after 48 hours incubation with 
0.50mM ALA (Figure 2). Compared to cells incubated without ALA, a relative fluorescence increase of 39.4-fold in 
CFPAC-1 and 2.7-fold in PANC-1 was seen. ALA concentrations above 0.50mM did not result in higher fluorescence. In 
contrast, the control cell line H6c7 showed progressively increasing fluorescence with increasing ALA concentrations. The 
highest cancer/control cell fluorescence ratios (a surrogate for the Rose criterion) for ALA were after 48 hours incubation 
with 0.25mM ALA; 122.9 in CFPAC-1 and 9.7 in PANC-1. At the more clinically relevant time point of 4 hours (current 
oral preparations of ALA are administered 3-6 hours pre-surgery) the highest cancer/control cell fluorescence ratios were 





CFPAC-1 displayed very high ALA-induced PpIX fluorescence (maximum increase >120-fold) compared to the control 
cell line H6c7. In contrast, PANC-1 showed only mildly increased fluorescence compared to H6c7, with a maximum 
fluorescence fold increase of 9.7. This difference is most likely due to variations in the relative up- or downregulation of 
the enzymes and transporters involved in the haem biosynthesis pathway secondary to ALA exposure (see abstract 11070-
210). Using the Rose criterion as a standard cut-off for effective FGS, ALA has the potential to play a role in FGS in 
pancreatic cancer in ALA-susceptible cancers. An early phase clinical trial is warranted to investigate the effect of ALA 
FGS in pancreatic cancer surgery as a photodiagnostic tool. 
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Figure 2 Relative fluorescence of pancreatic cancer cell lines CFPAC-1 and PANC-1 and pancreatic ductal cell line H6c7 following 4, 
8, 24 or 48 hours incubation with increasing doses of ALA (normalized to 100). Error bars on CFPAC-1 smaller than data 
points. 
 








   H6c7 
 
 
 = 4 hours,  = 8 hours,  = 24 hours,  = 48 hours  
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